Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Lyell Immunopharma Inc’s stock clocked out at $0.44, up 5.69% from its previous closing price of $0.41. In other words, the price has increased by $5.69 from its previous closing price. On the day, 0.98 million shares were traded. LYEL stock price reached its highest trading level at $0.4398 during the session, while it also had its lowest trading level at $0.3931.
Ratios:
To gain a deeper understanding of LYEL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.06 and its Current Ratio is at 7.06. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on October 30, 2024, Downgraded its rating to Underperform and sets its target price to $1 from $6 previously.
On June 27, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $1.
JP Morgan Downgraded its Overweight to Neutral on August 28, 2023, whereas the target price for the stock was revised from $15 to $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 31 ’25 when BRAWLEY OTIS W bought 35,640 shares for $0.56 per share. The transaction valued at 19,958 led to the insider holds 35,640 shares of the business.
Ramachandra Sumant bought 200,000 shares of LYEL for $115,220 on Mar 21 ’25. The Director now owns 200,000 shares after completing the transaction at $0.58 per share. On Mar 14 ’25, another insider, Klausner Richard, who serves as the Director of the company, bought 158,000 shares for $0.60 each. As a result, the insider paid 94,942 and bolstered with 843,365 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 129457912 and an Enterprise Value of -182101136. For the stock, the TTM Price-to-Sale (P/S) ratio is 2157.64 while its Price-to-Book (P/B) ratio in mrq is 0.34. Its current Enterprise Value per Revenue stands at -2985.265 whereas that against EBITDA is 0.914.
Stock Price History:
The Beta on a monthly basis for LYEL is -0.14, which has changed by -0.81708336 over the last 52 weeks, in comparison to a change of 0.059571505 over the same period for the S&P500. Over the past 52 weeks, LYEL has reached a high of $3.14, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is -25.06%, while the 200-Day Moving Average is calculated to be -56.67%.
Shares Statistics:
It appears that LYEL traded 1.01M shares on average per day over the past three months and 736760 shares per day over the past ten days. A total of 294.88M shares are outstanding, with a floating share count of 124.83M. Insiders hold about 57.72% of the company’s shares, while institutions hold 22.45% stake in the company. Shares short for LYEL as of 1743379200 were 5711632 with a Short Ratio of 5.63, compared to 1740700800 on 8087277. Therefore, it implies a Short% of Shares Outstanding of 5711632 and a Short% of Float of 2.5999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
